Skip to content

Study · Systematic review · n = 3,222 · 2016

2 results

Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme.

Montanya E, Fonseca V, Colagiuri S, Blonde L, Donsmark M, Nauck MA

Diabetes, obesity & metabolism2 Feb 2016Cited by 11 (Europe PMC)

PMID26662611 (opens in a new tab)PMCIDPMC5067695 (opens in a new tab)DOI10.1111/dom.12617 (opens in a new tab)PepBankPUB-26662611
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a patient-level meta-analysis of seven phase III trials in type 2 diabetes, baseline BMI was not significantly correlated with HbA1c reduction on liraglutide 1.2 mg.

    In plain wordsIn adults with type 2 diabetes, the HbA1c drop on liraglutide 1.2 mg did not depend on starting BMI.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c reduction by baseline BMI, liraglutide 1.2 mg
    Study

    n = 3,222

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mgAs given in this study (human).

    Source sentences

    Summary
    identified no significant correlation between baseline BMI (<20 kg/m(2) up to 45 kg/m(2) ) and HbA1c reduction for placebo or liraglutide 1.2 mg
    1 context sentence
    Summary · context
    pooled data from seven phase III trials [LEAD-1-6 and the liraglutide versus sitagliptin trial (LIRA-DPP-4)] for liraglutide 1.2, 1.8 mg and placebo (n = 3222)
  2. 02HumanSystematic reviewEfficacy outcome

    In a patient-level meta-analysis of seven phase III trials in type 2 diabetes, baseline BMI showed a modest, clinically non-relevant association with HbA1c reduction on liraglutide 1.8 mg: 0.10%-point greater reduction per 10 kg/m(2) higher BMI.

    In plain wordsIn adults with type 2 diabetes, a higher starting BMI went with a slightly bigger HbA1c drop on liraglutide 1.8 mg, too small to matter.

    Peptide
    Liraglutide
    Outcome
    Not applicableHbA1c reduction by baseline BMI, liraglutide 1.8 mg
    Study

    n = 3,222

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    HbA1c reduction per 10 kg/m(2) higher baseline BMI
    0.1 %-point
    liraglutide 1.8 mg

    Source sentences

    Summary
    a modest, clinically non-relevant, association for liraglutide 1.8 mg [-0.010 (95% confidence interval -0.020, -0.001)], whereby a 10 kg/m(2) increase in baseline BMI corresponded to 0.10%-point (1.1 mmol/mol) greater HbA1c reduction
    1 context sentence
    Summary · context
    pooled data from seven phase III trials [LEAD-1-6 and the liraglutide versus sitagliptin trial (LIRA-DPP-4)] for liraglutide 1.2, 1.8 mg and placebo (n = 3222)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.